Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransCode Therapeutics ( (RNAZ) ) has issued an announcement.
On October 8, 2025, TransCode Therapeutics announced the acquisition of Polynoma LLC, a biotechnology company developing a vaccine for melanoma, and a concurrent $25 million investment from CK Life Sciences. This acquisition and investment are expected to enhance TransCode’s pipeline, particularly advancing its lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial. The company’s leadership saw changes with Philippe Calais becoming CEO and Elizabeth Czerepak joining as an independent board member. The strategic moves aim to position TransCode as a leading oncology company, leveraging synergies between Polynoma’s vaccine and TransCode’s microRNA technologies to benefit cancer patients.
The most recent analyst rating on (RNAZ) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis, and it has a portfolio of other RNA therapeutic candidates aimed at overcoming RNA delivery challenges to treat various cancers.
Average Trading Volume: 88,550
Technical Sentiment Signal: Sell
Current Market Cap: $9.84M
For detailed information about RNAZ stock, go to TipRanks’ Stock Analysis page.